AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Short Interest Update

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) was the target of a large decrease in short interest during the month of February. As of February 13th, there was short interest totaling 142,902 shares, a decrease of 56.5% from the January 29th total of 328,268 shares. Currently, 4.4% of the shares of the stock are sold short. Based on an average daily volume of 7,677,784 shares, the short-interest ratio is presently 0.0 days. Based on an average daily volume of 7,677,784 shares, the short-interest ratio is presently 0.0 days. Currently, 4.4% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, Zacks Research downgraded shares of AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy”.

Institutional Trading of AIM ImmunoTech

Institutional investors and hedge funds have recently modified their holdings of the business. Corient Private Wealth LLC bought a new stake in shares of AIM ImmunoTech during the 2nd quarter valued at about $87,000. DRW Securities LLC increased its position in shares of AIM ImmunoTech by 60.6% in the fourth quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock worth $79,000 after purchasing an additional 26,254 shares during the last quarter. Finally, Sabby Management LLC purchased a new stake in AIM ImmunoTech in the third quarter valued at approximately $79,000. Hedge funds and other institutional investors own 12.02% of the company’s stock.

AIM ImmunoTech Stock Down 8.1%

Shares of AIM traded down $0.08 during mid-day trading on Friday, reaching $0.91. 132,155 shares of the stock traded hands, compared to its average volume of 3,954,684. AIM ImmunoTech has a 1 year low of $0.77 and a 1 year high of $36.00. The firm has a fifty day moving average price of $1.18 and a 200 day moving average price of $1.82.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.